418 related articles for article (PubMed ID: 29477794)
1. Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group.
Melchardt T; Magnes T; Hufnagl C; Thorner AR; Ducar M; Neureiter D; Tränkenschuh W; Klieser E; Gaggl A; Rösch S; Rasp G; Hartmann TN; Pleyer L; Rinnerthaler G; Weiss L; Greil R; Egle A
Eur J Cancer; 2018 Apr; 93():69-78. PubMed ID: 29477794
[TBL] [Abstract][Full Text] [Related]
2. Survival After Distant Metastasis in Head and Neck Cancer.
Wiegand S; Zimmermann A; Wilhelm T; Werner JA
Anticancer Res; 2015 Oct; 35(10):5499-502. PubMed ID: 26408715
[TBL] [Abstract][Full Text] [Related]
3. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
4. Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma.
Peng CH; Liao CT; Ng KP; Tai AS; Peng SC; Yeh JP; Chen SJ; Tsao KC; Yen TC; Hsieh WP
Oncotarget; 2015 Aug; 6(23):19891-906. PubMed ID: 26087196
[TBL] [Abstract][Full Text] [Related]
5. Molecular Characterization of Locally Relapsed Head and Neck Cancer after Concomitant Chemoradiotherapy.
de Roest RH; Mes SW; Poell JB; Brink A; van de Wiel MA; Bloemena E; Thai E; Poli T; Leemans CR; Brakenhoff RH
Clin Cancer Res; 2019 Dec; 25(23):7256-7265. PubMed ID: 31439582
[TBL] [Abstract][Full Text] [Related]
6. [Outcome and prognostic factors of 125 loco-regionally advanced head and neck squamous cell carcinoma treated with multi-modality treatment].
Qian W; Zhu G; Ji Q; Guo Y; Wang Y; Wang Y
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):217-22. PubMed ID: 24785284
[TBL] [Abstract][Full Text] [Related]
7. The gene expression profile of inflammatory, hypoxic and metabolic genes predicts the metastatic spread of human head and neck squamous cell carcinoma.
Clatot F; Gouérant S; Mareschal S; Cornic M; Berghian A; Choussy O; El Ouakif F; François A; Bénard M; Ruminy P; Picquenot JM; Jardin F
Oral Oncol; 2014 Mar; 50(3):200-7. PubMed ID: 24387976
[TBL] [Abstract][Full Text] [Related]
8. The subclonal structure and genomic evolution of oral squamous cell carcinoma revealed by ultra-deep sequencing.
Tabatabaeifar S; Thomassen M; Larsen MJ; Larsen SR; Kruse TA; Sørensen JA
Oncotarget; 2017 Mar; 8(10):16571-16580. PubMed ID: 28157713
[TBL] [Abstract][Full Text] [Related]
9. Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx.
Spector JG; Sessions DG; Haughey BH; Chao KS; Simpson J; El Mofty S; Perez CA
Laryngoscope; 2001 Jun; 111(6):1079-87. PubMed ID: 11404625
[TBL] [Abstract][Full Text] [Related]
10. Current role of gene therapy in head and neck cancer.
Ganly I; Soutar DS; Kaye SB
Eur J Surg Oncol; 2000 Jun; 26(4):338-43. PubMed ID: 10873352
[TBL] [Abstract][Full Text] [Related]
11. Predictive factors for long-term survival in head and neck squamous cell carcinoma patients with distant metastasis after initial definitive treatment.
Kang HS; Roh JL; Kim MJ; Cho KJ; Lee SW; Kim SB; Choi SH; Nam SY; Kim SY
J Cancer Res Clin Oncol; 2016 Jan; 142(1):295-304. PubMed ID: 26341665
[TBL] [Abstract][Full Text] [Related]
12. Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.
Lluch A; González-Angulo AM; Casadevall D; Eterovic AK; Martínez de Dueñas E; Zheng X; Guerrero-Zotano Á; Liu S; Pérez R; Chen K; Chacón JI; Mills GB; Antolín S; Blancas I; López-Serra P; Carrasco E; Caballero R; Prat A; Rojo F; Gonzalez-Perez A; Meric-Bernstam F; Albanell J
Eur J Cancer; 2019 Oct; 120():54-64. PubMed ID: 31491604
[TBL] [Abstract][Full Text] [Related]
13. Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.
Hedberg ML; Goh G; Chiosea SI; Bauman JE; Freilino ML; Zeng Y; Wang L; Diergaarde BB; Gooding WE; Lui VW; Herbst RS; Lifton RP; Grandis JR
J Clin Invest; 2016 Jan; 126(1):169-80. PubMed ID: 26619122
[TBL] [Abstract][Full Text] [Related]
14. Prospective assessment of the clinical benefit of a tailored cancer gene set built on a next-generation sequencing platform in patients with recurrent or metastatic head and neck cancer.
Westbrook TC; Hagemann IS; Ley J; Chen K; Palka K; Liu J; Chen L; Oppelt P; Adkins D
Med Oncol; 2019 Dec; 37(2):12. PubMed ID: 31865465
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
16. Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.
Eder T; Hess AK; Konschak R; Stromberger C; Jöhrens K; Fleischer V; Hummel M; Balermpas P; von der Grün J; Linge A; Lohaus F; Krause M; Baumann M; Stuschke M; Zips D; Grosu AL; Abdollahi A; Debus J; Belka C; Pigorsch S; Combs SE; Budach V; Tinhofer I;
Eur J Cancer; 2019 Jul; 116():67-76. PubMed ID: 31173964
[TBL] [Abstract][Full Text] [Related]
17. Is high-risk cutaneous squamous cell carcinoma of the head and neck a suitable candidate for current targeted therapies?
Zilberg C; Lee MW; Kraitsek S; Ashford B; Ranson M; Shannon K; Iyer NG; Ch'ng S; Low TH; Palme C; Clark J; Gupta R; Yu B
J Clin Pathol; 2020 Jan; 73(1):17-22. PubMed ID: 31300530
[TBL] [Abstract][Full Text] [Related]
18. CAFE MOCHA: An Integrated Platform for Discovering Clinically Relevant Molecular Changes in Cancer-An Example of Distant Metastasis- and Recurrence-Linked Classifiers in Head and Neck Squamous Cell Carcinoma.
Krishnan NM; I M; Hariharan J; Panda B
JCO Clin Cancer Inform; 2018 Dec; 2():1-11. PubMed ID: 30652568
[TBL] [Abstract][Full Text] [Related]
19. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
20. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
